Jean Jacques Bienaime - Apr 14, 2022 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Chief Executive Officer, Director
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Apr 14, 2022
Transactions value $
-$462,000
Form type
4
Date filed
4/18/2022, 09:46 PM
Previous filing
Mar 17, 2022
Next filing
Apr 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $375K +10K +2.99% $37.46 345K Apr 14, 2022 Direct F1
transaction BMRN Common Stock Sale -$837K -10K -2.9% $83.66 335K Apr 14, 2022 Direct F1
holding BMRN Common Stock 248K Apr 14, 2022 Shares held by Jean-Jacques Bienaime Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -10K -11.76% $0.00 75K Apr 14, 2022 Common Stock 10K $37.46 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on December 9, 2021, as amended on March 11, 2022. Mr. Bienaime's former spouse will receive approximately 70% of the net proceeds from the shares sold in this transaction pursuant to a marital separation agreement between her and Mr. Bienaime.
F2 Reflects the number of options outstanding after the transactions from this specific stock option grant.